Preclinical and Translational Sciences
Eric Feeley, Ph.D.
Senior Field Applications Scientist
Gyros Protein Technologies
Warren, New Jersey
Description: The development of robust assays to assess pre-existing anti-drug antibodies (ADAs) or immunogenicity in response to biotherapeutic treatment in preclinical and clinical subjects faces challenges of time, sensitivity, and drug tolerance. New tools to accelerate and simplify anti-drug antibody (ADA) measurement across modalities are needed that address these requirements. Here we present ADA assay approaches for automating preclinical ADA screening using a generic assay measuring immune complexes, and drug-specific ADA assays for IgG- and AAV-based therapies using a well-established microfluidic platform.